Indications and uses
for relief of occasional constipation and restoring regularity natural bulk producing fiber encourages normal elimination without chemical stimulants
equate Fiber Therapy Original Texture Unflavored
- Manufacturer
- Wal-Mart Stores Inc | Konsyl Pharmaceuticals, Inc.
- Effective date
- 2018-12-05
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 6
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 00:44:44
Label at a glance#
Productequate Fiber Therapy Original Texture Unflavored
Active ingredientPSYLLIUM HUSK
Label structure10 sections
Dosage and administration
This product generally produces effect in 12-72 hours. Put one dose into an empty glass. Fill glass with at least 8 oz of water or your favorite beverage. Stir briskly and drink promptly. If mixture thickens, add more liquid and stir. mix this product (child or adult) dose with at least 8 ounces (a full glass) of water or other liquid taking this product without enough liquid may cause choking, see choking warning...
Label contents#
Full prescribing information#
Active Ingredients
Psyllium Husk 3.4g
Purpose
Bulk-forming laxative
Uses
- for relief of occasional constipation and restoring regularity
- natural bulk producing fiber encourages normal elimination without chemical stimulants
Warnings
Allergy alert
- may cause allergic reaction in people sensitive to inhaled or ingested psyllium
Choking
- taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking
Do not take this product if you have
- difficulty in swallowing
- if you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention
Ask a doctor before use if you have
- abdominal pain, nausea, vomiting or rectal bleeding
- a sudden change in bowel habits that persist over a period of 2 weeks
- constipation associated with gastrointestinal disorders
Ask a doctor or pharmacist before use if you are
- taking any other drug
- take this product 2 or more hours before or after other drugs
- all laxatives may affect how other drugs work
Stop use and ask a doctor if
- constipation persists beyond 7 days. This could be a sign condition
Keep out of reach of children
In case of overdose, get help or contact a Poison Control Center right away.
Directions
This product generally produces effect in 12-72 hours. Put one dose into an empty glass. Fill glass with at least 8 oz of water or your favorite beverage. Stir briskly and drink promptly. If mixture thickens, add more liquid and stir.
- mix this product (child or adult) dose with at least 8 ounces (a full glass) of water or other liquid
- taking this product without enough liquid may cause choking, see choking warning
- can be taken before or after meals
| Age | Dose |
| adults and children 12 years and older
| 1 rounded teaspoon (7g) in 8 oz of liquid, up to 3 times daily
|
| children 6 to under 12 years
| 1/2 adult dose in 8 oz of liquid, up to 3 times daily
|
| children under 6 years
| consult a doctor
|
other information
- each 7 g dose contains potassium 34mg; sodium 4 mg; calcium 8 mg
- store below 30
oC (86
oF), tightly closed to protect from humidity
Inactive Ingredients
sucrose
Distributed by:
- Wal-Mark Stores, Inc, Bentonville, AR 72716 Wal-Mart Stores, Inc, This product is not manufactured or distributed by Procter and Gamble, owner of the registered trademark Metamucil MultiHealth 34012 0611
Keep out of reach of children.
In case of an overdose, get medical help or contact a Poison Control Center right away.
Representative Label
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0681131064316 | GTIN-13: 0681131064316 EAN-13: 0681131064316 GTIN-12: 681131064316 UPC-A: 681131064316 GTIN storage (14 digits): 00681131064316 | OuterLabel80.jpg |
| Barcode | EAN-13 | 0681131699914 | GTIN-13: 0681131699914 EAN-13: 0681131699914 GTIN-12: 681131699914 UPC-A: 681131699914 GTIN storage (14 digits): 00681131699914 | OuterLabel.jpg |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| PSYLLIUM HUSK | ACTIVE INGREDIENT | 0SHO53407G | 4 | |
| PSYLLIUM HUSK | ACTIVE MOIETY | 0SHO53407G | 4 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 4 |
Products#
Every source-derived product name is available through these pages.
- equate Fiber Therapy Original Texture Unflavored
- PSYLLIUM HUSK
- SUCROSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 49035-043 | 49035-043-29, 49035-043-80 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| PSYLLIUM HUSK | 0SHO53407G | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7c47361f-0d18-5d41-e053-2a91aa0aea14 | 53e8fc4a-ffe7-48bc-afcf-5310240ac343 | 2018-12-05 | Warnings | 7c47361f-0d18-5d41-e053-2a91aa0aea14 53e8fc4a-ffe7-48bc-afcf-5310240ac343 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.